Pharming Group N.V. PHAR · Stock Open Pharming Group N.V. in new tab
Pharming Group N.V. Analysis (PHAR)
Is Pharming Group N.V. a good investment? Pharming Group N.V. (PHAR) is currently trading at 13.01 USD. Market analysts have a consensus price target of 34.35 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 68.49. This high multiple suggests investors have priced in significant future growth expectations.
Earnings Schedule: Pharming Group N.V. is expected to release its next earnings report on July 30, 2026. The market consensus estimate for Forward EPS is 0.07.
Investor FAQ
Does Pharming Group N.V. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Pharming Group N.V.?
Pharming Group N.V. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be July 30, 2026. The company currently has a trailing EPS of 0.19.
Company Profile
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K? inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Community Discussion